NIH initiative aims to tackle opioid misuse, addiction, enhance pain management

(JAMA Network) In the   JAMA Viewpoint, 'Helping to End Addiction Over the Long-Term: The Research Plan for the NIH HEAL Initiative,' National Institutes of Health Director   Francis S. Collins, M.D., Ph.D., and coauthors discuss an interdisciplinary program aimed at advancing addiction and pain research in the United States to improve treatments for opioid misuse and addiction and to enhance pain management.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news

Related Links:

The FDA this week approved the first generic version of Indivior‘s (LON:INDV) billion-dollar opioid addiction treatment, Suboxone. The generic buprenorphine and naloxone sublingual film, sold by Dr. Reddy’s Laboratories (NYSE:RDY) and Mylan (NSDQ:MYL), is designed to suppress withdrawal symptoms that crop in people addicted to opioids, as well as block the neurochemical effects of opioids. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first generic sublingual film to treat opioid addiction appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Dr. Reddy's Laboratories indivior Mylan Source Type: news
Earlier this year at the Health 2.0 WinterTech Conference, the Robert Wood Johnson Foundation (RWJF) and Catalyst @ Health 2.0 launched the RWJF Opioid Challenge, an initiative aimed at bringing together healthcare and technology innovators to s...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Net News Pain Management Psychiatry Public Health Rehab Source Type: blogs
AbstractPurpose of ReviewWith the rise of the opioid epidemic, anesthesiologists will find themselves faced with opioid-addicted patients more frequently. Addiction to opioids may also occur concurrently with abuse of other non-opioid medications. Our review article seeks to outline an armamentarium of pain management strategies in the perioperative period for these patients with addiction to opioid and non-opioid medications.Recent FindingsStatistics from the CDC demonstrate a shocking increase in opioid prescription rates and opioid-related deaths. Furthermore, opioid-addicted patients have notoriously undertreated pain ...
Source: Current Pain and Headache Reports - Category: Neurology Source Type: research
The HEAL initiative will focus on improving treatments for patients who misuse or are addicted to opioids and enhancing strategies for effective pain management.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
(MedPage Today) -- HEAL initiative seeks to combat addiction, improve pain management
Source: MedPage Today Neurology - Category: Neurology Source Type: news
The plan focuses on improving treatments for opioid misuse and addiction, and enhancing strategies for pain management.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
CAMBRIDGE (CBS NEWS) — Researchers in Massachusetts believe they may be on the brink of creating a revolutionary non-addictive painkiller. Developed by Blue Therapeutics, Blue-181 could be a big step forward in dealing with the growing opioid crisis. The team there said it wanted to make a drug that is a total replacement for the opioids currently on the market – something that people could safely stop using without the possible dangerous side effects. Mark Loccisano felt a gratification from painkillers with his very first pill. They were prescribed by a doctor for a sports injury. It was the beginning of an o...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Cambridge Local TV opioid crisis Source Type: news
ConclusionEmotion dysregulation is an important and malleable treatment target with the potential to reduce or prevent opioid misuse and suicidality among opioid-treated chronic pain patients.
Source: Borderline Personality Disorder and Emotion Dysregulation - Category: Psychiatry Source Type: research
It isn't the first time FDA has turned to medtech for solutions to opioid misuse and abuse, but now the agency is officially challenging the medical device and diagnostics industry to step up in the ongoing war on opioids. FDA recently launched an innovation challenge to spur the development of devices, digital health technologies, and diagnostic tests that could provide novel solutions in response to the opioid epidemic. That's not to say the industry hasn't already put forth some effort in this area. Manufacturers of naloxone products – a drug designed to potentially save a person's life in the event of an opioid o...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Digital Health Source Type: news
Conclusion: PCIA provided timely, safe, and satisfactory analgesia for advanced cancer patients with pain and may be useful for titration of opioids, management of severe breakthrough pain, and conversion to oral analgesia. There was no significant difference of analgesic effect and side effect among the hydromorphone, sufentanil, and oxycodone. PMID: 29849846 [PubMed - in process]
Source: Pain Research and Management - Category: Anesthesiology Authors: Tags: Pain Res Manag Source Type: research
More News: Addiction | International Medicine & Public Health | National Institutes of Health (NIH) | Pain | Pain Management | Science | USA Health